Shares of Polaryx Therapeutics, Inc. (NASDAQ:PLYX – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the five ratings firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $7.67.
Several research analysts have commented on PLYX shares. Weiss Ratings restated a “sell (e)” rating on shares of Polaryx Therapeutics in a report on Monday, September 28th. Zacks Research upgraded Polaryx Therapeutics to a “hold” rating in a report on Friday, July 10th. Raymond James Financial began coverage on Polaryx Therapeutics in a research report on Thursday, August 13th. They set a “strong-buy” rating and a $6.00 price target on the stock. HC Wainwright assumed coverage on Polaryx Therapeutics in a research note on Thursday, July 9th. They set a “buy” rating and a $7.00 price target on the stock. Finally, Wall Street Zen upgraded Polaryx Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 12th.
Read Our Latest Stock Analysis on Polaryx Therapeutics
Polaryx Therapeutics Price Performance
Polaryx Therapeutics stock opened at $1.75 on Tuesday. The firm has a 50-day moving average of $2.00 and a two-hundred day moving average of $3.14. Polaryx Therapeutics has a 1 year low of $1.72 and a 1 year high of $48.91.
Polaryx Therapeutics (NASDAQ:PLYX – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02. Equities analysts forecast that Polaryx Therapeutics will post -0.22 EPS for the current fiscal year.
Polaryx Therapeutics Company Profile
We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.
Featured Stories
- Five stocks we like better than Polaryx Therapeutics
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Polaryx Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polaryx Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
